NASDAQ:CABA

Cabaletta Bio (CABA) Stock Forecast, Price & News

$11.11

+1.02 (+10.11%)

(As of 03:46 PM ET)

Compare

Today's Range: $9.89
▼
$11.14
50-Day Range: $7.10
▼
$13.16
52-Week Range: $0.59
▼
$13.44

Volume: 340,361 shs
Average Volume: 476,668 shs
Market Capitalization: $348.41 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $14.17

Cabaletta Bio MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 31.3% Upside
$14.17 Price Target
Short Interest: Bearish
12.69% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$259,820 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.87) to ($1.60) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.85 out of 5 stars

Medical Sector

949th out of 1,980 stocks

Biological Products, Except Diagnostic Industry

141st out of 330 stocks

3.5

Analyst's Opinion

Consensus Rating
Cabaletta Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $14.17, Cabaletta Bio has a forecasted upside of 31.3% from its current price of $10.79.
Amount of Analyst Coverage
Cabaletta Bio has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
12.69% of the outstanding shares of Cabaletta Bio have been sold short.
Short Interest Ratio / Days to Cover
Cabaletta Bio has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.
Change versus previous month
Short interest in Cabaletta Bio has recently decreased by 0.50%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Cabaletta Bio does not currently pay a dividend.
Dividend Growth
Cabaletta Bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CABA.

0.6

News and Social Media Coverage

Search Interest
8 people have searched for CABA on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cabaletta Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $259,820.00 in company stock.
Percentage Held by Insiders
12.33% of the stock of Cabaletta Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
62.12% of the stock of Cabaletta Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Cabaletta Bio are expected to grow in the coming year, from ($1.87) to ($1.60) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cabaletta Bio is -5.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cabaletta Bio is -5.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cabaletta Bio has a P/B Ratio of 3.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Cabaletta Bio (NASDAQ:CABA) Stock

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Receive CABA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cabaletta Bio and its competitors with MarketBeat's FREE daily newsletter.

CABA Stock News Headlines

May 24, 2023 | finance.yahoo.com

Institutional investors in Cabaletta Bio, Inc. (NASDAQ:CABA) lost 18% last week but have reaped the benefits of longer-term growth

May 22, 2023 | finance.yahoo.com

Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares

June 1, 2023 | Edge On The Street (Ad)

The $193 Billion US-China War You Don't Know About

They're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.

May 22, 2023 | bizjournals.com

Prelude Therapeutics, Cabaletta Bio expect to raise up to $161M combined in public stock sales

May 18, 2023 | msn.com

These stocks are seeing some short squeeze action - watch out above

May 18, 2023 | msn.com

Cabaletta Bio up 1%, prices $87M offering

May 18, 2023 | finance.yahoo.com

Cabaletta Bio Announces Pricing of Public Offering of Common Stock

May 17, 2023 | seekingalpha.com

Cabaletta Bio jumps 16% as FDA clears trial for myositis candidate

June 1, 2023 | Edge On The Street (Ad)

The $193 Billion US-China War You Don't Know About

May 17, 2023 | finance.yahoo.com

Cabaletta Bio Announces Proposed Public Offering of Common Stock

May 17, 2023 | marketwatch.com

Thinking about buying stock in Cabaletta Bio, SNDL, Roblox, DraftKings, or Riot Platforms?

May 16, 2023 | marketwatch.com

Cabaletta Bio Shares Rose 15% After FDA Approves IND Application for CABA-201

May 16, 2023 | msn.com

Cabaletta Bio Jumps after New Trial Plans

May 16, 2023 | finance.yahoo.com

Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis

May 11, 2023 | marketwatch.com

10-Q: CABALETTA BIO, INC.

May 11, 2023 | seekingalpha.com

Cabaletta Bio GAAP EPS of -$0.45 beats by $0.02

May 11, 2023 | msn.com

Recap: Cabaletta Bio Q1 Earnings

May 11, 2023 | finance.yahoo.com

Cabaletta Bio Reports First Quarter 2023 Financial Results and Provides Business Update

May 3, 2023 | americanbankingnews.com

Short Interest in Cabaletta Bio, Inc. (NASDAQ:CABA) Grows By 9.8%

May 2, 2023 | finance.yahoo.com

Cabaletta Bio to Present at the American Society of Gene and Cell Therapy 26th Annual Meeting

May 1, 2023 | finance.yahoo.com

Cabaletta Bio Receives FDA Fast Track Designation for CABA-201

April 25, 2023 | finance.yahoo.com

Great news for Cabaletta Bio, Inc. (NASDAQ:CABA): Insiders acquired stock in large numbers last year

April 25, 2023 | finance.yahoo.com

Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

April 13, 2023 | finance.yahoo.com

Cabaletta Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference

April 3, 2023 | americanbankingnews.com

Cabaletta Bio's (CABA) "Buy" Rating Reiterated at HC Wainwright

March 31, 2023 | markets.businessinsider.com

Mizuho Securities Sticks to Its Buy Rating for Cabaletta Bio (CABA)

March 31, 2023 | msn.com

Cabaletta CAR T cell therapy for lupus gets FDA nod to enter trial

See More Headlines

CABA Price History

30 days | 90 days | 365 days | Advanced Chart

CABA Company Calendar

Last Earnings: 3/16/2023
Today: 6/01/2023
Next Earnings (Estimated): 8/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CABA
CUSIP: N/A
CIK: 1759138
Web: www.cabalettabio.com
Phone: 267-759-3100
Fax: N/A
Employees: 53
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $14.17
High Stock Price Forecast: $18.00
Low Stock Price Forecast: $10.00
Forecasted Upside/Downside: +31.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.81)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-52,970,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -59.20%
Return on Assets: -53.98%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.29
Quick Ratio: 10.29

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.92 per share
Price / Book: 3.70

Miscellaneous

Outstanding Shares: 31,360,000
Free Float: 27,490,000
Market Cap: $338.37 million
Optionable: Not Optionable
Beta: 2.54

Key Executives

Dr. Steven A. Nichtberger M.D. (Age 61)
Co-Founder, Chairman, CEO & Pres
Comp: $904.13k

Dr. Gwendolyn K. Binder Ph.D. (Age 47)
Pres of Science & Technology
Comp: $654.51k

Dr. David J. Chang FACR (Age 59)
M.D., M.P.H., Chief Medical Officer
Comp: $656.29k

Dr. Michael C. Milone M.D.
Ph.D., Co-Founder & Co-Chair of Scientific Advisory Board

Dr. Aimee Payne M.D.
Ph.D., Co-Founder & Co-Chair of Scientific Advisory Board

Mr. Anup Marda M.B.A. (Age 45)
Chief Financial Officer

Dr. Samik Basu M.D.
Chief Scientific Officer

Mr. Michael Gerard J.D. (Age 42)
Gen. Counsel & Sec.

Ms. Heather Harte-Hall M.Sc.
Chief Compliance Officer

Ms. Martha O'Connor
Chief HR Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CABA Stock - Frequently Asked Questions

Should I buy or sell Cabaletta Bio stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cabaletta Bio in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CABA shares.
View CABA analyst ratings or view top-rated stocks.
What is Cabaletta Bio's stock price forecast for 2023?: 5 brokers have issued twelve-month price objectives for Cabaletta Bio's stock. Their CABA share price forecasts range from $10.00 to $18.00. On average, they expect the company's share price to reach $14.17 in the next year. This suggests a possible upside of 31.3% from the stock's current price.
View analysts price targets for CABA or view top-rated stocks among Wall Street analysts.
How have CABA shares performed in 2023?: Cabaletta Bio's stock was trading at $9.25 on January 1st, 2023. Since then, CABA shares have increased by 16.6% and is now trading at $10.79.
View the best growth stocks for 2023 here.
When is Cabaletta Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our CABA earnings forecast.
How were Cabaletta Bio's earnings last quarter?: Cabaletta Bio, Inc. (NASDAQ:CABA) posted its earnings results on Thursday, March, 16th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.47) by $0.05.
What ETFs hold Cabaletta Bio's stock?: ETFs with the largest weight of Cabaletta Bio (NASDAQ:CABA) stock in their portfolio include Alger Mid Cap 40 ETF (FRTY).Alger 35 ETF (ATFV).

What other stocks do shareholders of Cabaletta Bio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cabaletta Bio investors own include Alector (ALEC), Editas Medicine (EDIT), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Homology Medicines (FIXX), Skyworks Solutions (SWKS), CrowdStrike (CRWD), Precision BioSciences (DTIL), Invitae (NVTA) and Pfizer (PFE).
When did Cabaletta Bio IPO?: (CABA) raised $87 million in an initial public offering on Friday, October 25th 2019. The company issued 5,800,000 shares at $14.00-$16.00 per share. Morgan Stanley, Cowen and Company and Evercore Group served as the underwriters for the IPO.
What is Cabaletta Bio's stock symbol?: Cabaletta Bio trades on the NASDAQ under the ticker symbol "CABA."
Who are Cabaletta Bio's major shareholders?: Cabaletta Bio's stock is owned by many different retail and institutional investors. Top institutional investors include Fred Alger Management LLC (13.62%), Commodore Capital LP (6.22%), Jennison Associates LLC (2.65%), Perceptive Advisors LLC (2.31%), BlackRock Inc. (0.79%) and Geode Capital Management LLC (0.75%). Insiders that own company stock include Anup Marda, Catherine Bollard, Gwendolyn Binder, Steven Nichtberger and Ventures V LP 5Am.
View institutional ownership trends.
How do I buy shares of Cabaletta Bio?: Shares of CABA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Cabaletta Bio's stock price today?: One share of CABA stock can currently be purchased for approximately $10.79.
How much money does Cabaletta Bio make?: Cabaletta Bio (NASDAQ:CABA) has a market capitalization of $338.37 million. The company earns $-52,970,000.00 in net income (profit) each year or ($1.81) on an earnings per share basis.
How can I contact Cabaletta Bio?: Cabaletta Bio's mailing address is 2929 ARCH STREET SUITE 600, PHILADELPHIA PA, 19104. The official website for the company is www.cabalettabio.com. The company can be reached via phone at 267-759-3100 or via email at investors@cabalettabio.com.

This page (NASDAQ:CABA) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial